United States

BioInvent International AB (BINV.ST)

BINV.ST on Stockholm Stock Exchange

20 Oct 2017
Change (% chg)

-0.01kr (-0.35%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Bioinvent Q2 net loss decreases yr/yr
Wednesday, 26 Jul 2017 02:30am EDT 

July 26 (Reuters) - Bioinvent :Q2 net sales amounted to SEK 11 (10) million..Q2 earnings after tax: SEK -23 (-27) million..  Full Article

BioInvent swings to net loss in Q1
Wednesday, 17 May 2017 05:00am EDT 

May 17 (Reuters) - BioInvent :Q1 net sales amounted to SEK 13 (29) million.Q1 earnings after tax SEK -22 (0.3) million.  Full Article

BioInvent extends contract with existing customer, expects SEK 8 mln in revenue
Monday, 29 Aug 2016 02:30am EDT 

Bioinvent International Ab : BioInvent extends manufacturing services contract with major global pharmaceutical client; expects to generate approximately SEK 8 million in revenue Further company coverage: [BINV.ST] (Reporting by Stockholm Newsroom) ((stockholm.newsroom@thomsonreuters.com; +46-(0)8-700 10 17;)).  Full Article

BioInvent Q2 net loss widens, reports higher sales
Tuesday, 26 Jul 2016 02:36am EDT 

BioInvent : Says net sales for april-june 2016 amounted to sek 10 (3.7) million. . Says earnings after tax for april-june 2016: sek -27 (-25) million. For the original story click here: http://mb.cision.com/Main/583/2050777/543529.pdf Further company coverage: [BINV.ST] (Stockholm Newsroom) ((stockholm.newsroom@thomsonreuters.com; +46 (0)8-700 10 10;)).  Full Article

BioInvent International , Oncurious and NMTRC starts Phase I/IIa study with TB-403
Monday, 2 May 2016 01:30am EDT 

BioInvent International AB:BioInvent, Oncurious NV and NMTRC initiating Phase I/IIa study with TB-403 for the treatment of medulloblastoma.Study will evaluate the safety and tolerability, and explore the preliminary efficacy, of TB-403 for the treatment of relapsed or refractory medulloblastoma, a rare, life-threatening brain tumor that mainly affects children.Says treatment with TB-403 in pre-clinical models for medulloblastoma has demonstrated beneficial effects on tumor growth and survival.Says TB-403 has been shown to have a favorable safety profile in previous clinical trials in healthy volunteers and adult patients with various types of solid tumors.The drug candidate TB-403 is jointly owned by BioInvent and the Belgian biopharma company Oncurious NV.  Full Article

BioInvent International says multiple myeloma phase II study of antibody BI-505 ready to start
Monday, 18 Apr 2016 02:40am EDT 

BioInvent International AB:Multiple myeloma phase II study of Bioinvent's antibody BI-505 ready to start.  Full Article

BioInvent says completes SEK 234 mln share issue
Thursday, 14 Apr 2016 08:00pm EDT 

BioInvent International AB:Says the company's rights issue has been completed.Says two new share issues will provide BioInvent with around 234 million Swedish crowns before issue costs.Says in parallel with the rights issue BioInvent is carrying out a directed share issue (private placement) to US specialist investor Omega Funds for 43 million crowns.  Full Article

BioInvent International AB granted European patent for immune-oncology antibody
Wednesday, 16 Mar 2016 03:40am EDT 

BioInvent International AB:Is granted a patent in Europe for the immune-oncology antibody BI-505.Says plans to shortly initiate a Phase II trial with BI-505 in patients with multiple myeloma, with the aim to prevent or significantly delay relapse of this serious form of hematologic cancer.Says the European patent for BI-505 will enter into force on 6 April 2016 and will expire in 2026.Says corresponding patents have already been granted in the U.S., Japan, Australia, China, South Korea and Russia, among other countries.  Full Article

BioInvent International and Oncurious partner with US research consortium
Tuesday, 15 Mar 2016 02:15am EDT 

BioInvent International AB:Bioinvent and Oncurious partner with US research consortium to accelerate phase I/IIa trial of TB-403.  Full Article

BioInvent says gets FDA approval for study on TB-403
Thursday, 7 Jan 2016 06:30am EST 

BioInvent International AB:Says announces FDA acceptance of the investigational new drug application for the phase I/IIa study with TB-403.Says the study, which is planned to commence in Q1 2016, will be conducted at a number of specialist centers in the United States.Says initial results from the study are expected by early 2017.  Full Article

BRIEF-The japanese patent office intends to grant Bioinvent's immune-oncology antibody patent

* The japanese patent office intends to grant bioinvent's important patent relating to the immune-oncology antibody bi-1206